SCHEMBL6521859

SCHEMBL6521859

CC(C)(C)NC(=O)Nc1cc(NC(=O)NCCc2ccccc2)cc(Cl)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
MAPT P10636 3/20 0.58
CNR1 P21554 6/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
EPHX1 P07099 1/20 0.49
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
TRPV1 Q8NER1 1/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
TP53 P04637 1/20 0.45
GHSR Q92847 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6251887 0.89 NPC1 (0.46) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL6522452 0.86 ALDH1A1 (0.48) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL6568667 0.84 CA1 (0.56) NPC1RAB9AMAPTSMN1; SMN2MEN1
SCHEMBL4351106 0.84 CNR1 (0.68) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL6250660 0.83 CNR1 (0.52) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL4345315 0.81 CNR1 (0.59) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL6526557 0.80 EPHX1 (0.51) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL12846673 0.79 SMN1; SMN2 (0.50) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL6521517 0.79 EPHX1 (0.50) NPC1RAB9AMAPTCNR1SMN1; SMN2
SCHEMBL4357505 0.78 CNR1 (0.60) NPC1RAB9AMAPTCNR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885RAB9A 4228/4885MAPT 4439/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885RAB9A 4588/4885MAPT 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.